Edwards Lifesciences Corp (EW) Options Risk Score

Run a full EW options risk analysis

See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.

Is it risky to sell options on Edwards Lifesciences Corp (EW) right now?

Edwards Lifesciences Corp (EW) currently scores 35 out of 100 for options catalyst risk (LOW) over a 4-week expiry window. What pushes it there: an upcoming earnings report, 1 recent news item, 10 active legal filings and 20 clinical-trial catalysts, all landing inside the 4-week window. A LOW score (under 45) means the scan found no dated catalyst for EW inside the window. Read it as a clean calendar rather than a safe stock — surprises are by definition unscheduled.

EW shows an IV Rank of 40, near the low end of its one-year range — options are relatively cheap, which favours option buyers over sellers, with a current implied volatility of about 30%. IV Rank is the most useful figure for deciding whether to sell or buy premium on EW.

EW reports on 2026-10-29. Any expiry beyond that date carries the gap, and the implied volatility priced in beforehand typically collapses the morning after.

Edwards Lifesciences Corp (EW) current implied volatility and IV Rank

EW's IV Rank stands at 40 right now with implied volatility around 30%, alongside a TickerRisk options-risk score of 35/100. That is toward the bottom of its 12-month range, so premium is thin. Selling here pays poorly for the risk taken; if you expect a move, buying the move is the cheaper side.

Unsure how to act on this? What IV Rank is worth selling at →

Edwards Lifesciences Corp (EW) next earnings date — 2026-10-29

Edwards Lifesciences Corp (EW) reports earnings on 2026-10-29 — about 53 days away, which falls inside a typical options expiry window. EW's IV Rank is currently 40. Earnings are the single biggest scheduled catalyst for an overnight gap: implied volatility usually runs up into the report and collapses immediately after (the IV crush). Selling premium into the event captures that crush but exposes you to the gap; buying premium needs a move large enough to beat the elevated IV you paid.

TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer